María Natalia GaNdur Quiroga, Chief of the Division of Genitourinary Medical Oncology at the Angel H. Roffo Oncology Institute, shared Oncology Tube’s post on X, adding:
“Perioperative EV + pembrolizumab is now a major new option in cisplatin-eligible MIBC.
KEYNOTE-B15 / EV-304 | N=808
- EFS: NR vs 48.5 mo with gem/cis / HR 0.53
- OS: NR vs NR / HR 0.65
- pCR: 55.8% vs 32.5%
This phase 3 trial moves EV + pembrolizumab firmly into the curative-intent perioperative setting and challenges neoadjuvant cisplatin-based chemotherapy as the default approach for eligible patients.
Clinical takeaway: better disease control and deeper pathological response – but integration into practice will require careful attention to toxicity, patient selection, and sequencing.”
Quoting Oncology Tube’s post:
“WATCH: Padcev + Keytruda – cisplatin-eligible MIBC
- July 10, 2026 FDA (KEYNOTE-B15 / EV-304, N=808)
- EFS NR vs 48.5 mo vs gem/cis (HR 0.53)
- OS NR vs NR (HR 0.65); pCR 55.8% vs 32.5%
Perioperative EV + pembro vs neoadjuvant chemo.”
Other articles about MIBC on OncoDaily.